Mahdi Taha, DO, FACOI, FACP

home / authors / mahdi-taha-do-facoi-facp

Articles

KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice

Moshe Ornstein, MD, MA;Karine Tawagi, MD;Hans Hammers, MD;Mahdi Taha, DO, FACOI, FACP;Nataliya Mar, MD

September 13th 2024

Medical experts review long-term data from the KEYNOTE-B61 trial on pembrolizumab and lenvatinib, compare its efficacy and safety across non–clear cell RCC subtypes, and discuss dose management and safety relative to the CLEAR trial.

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates (insert the slide for case in this segment)

Moshe Ornstein, MD, MA;Karine Tawagi, MD;Hans Hammers, MD;Mahdi Taha, DO, FACOI, FACP;Nataliya Mar, MD

September 13th 2024

Medical experts outline the current first-line treatment options for advanced non–clear cell RCC, including the factors influencing agent selection, as well as discuss how recent NCCN guideline updates and label changes affect treatment decisions in community practice.

Challenges in Treating RCC From Community and Academic Settings

Moshe Ornstein, MD, MA;Karine Tawagi, MD;Hans Hammers, MD;Mahdi Taha, DO, FACOI, FACP;Nataliya Mar, MD

September 6th 2024

Medical experts explore the main challenges in treating non–clear cell RCC compared with clear cell RCC, discussing how these difficulties vary between community and academic settings.

Overview of RCC: Clear-Cell and Non–clear Cell

Moshe Ornstein, MD, MA;Karine Tawagi, MD;Hans Hammers, MD;Mahdi Taha, DO, FACOI, FACP;Nataliya Mar, MD

September 6th 2024

Medical experts give an overview of renal cell carcinoma (RCC), detailing the differences between clear cell and non–clear cell subtypes, the various forms of non–clear cell RCC, and the demographic and risk factor profiles associated with each subtype, while also discussing how histological differences influence prognosis.